Maintaining confidentiality of interim data to enhance trial integrity and credibility.
about
Randomized controlled trials - a matter of designEvaluating interventions for Ebola: The need for randomized trialsSharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.Protecting the confidentiality of interim data: addressing current challenges.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Ethical issues with the disclosure of surgical trial short-term data.Data monitoring committees, interim analysis and early termination in paediatric trials.Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.Should sponsors and DSMBs share interim results across trials?Data monitoring committees: Promoting best practices to address emerging challenges.Clinical trials: discerning hype from substance.Building a more connected DSMB: better integrating ethics review and safety monitoring.Identifying and addressing safety signals in clinical trials.Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.Adaptive methods: telling "the rest of the story".Blinded assessment of treatment effects utilizing information about the randomization block length.Data Monitoring Committees: Current issues.Adaptive designs in clinical trials: why use them, and how to run and report them.Response to the letter from Korn et al
P2860
Q26746217-047AC80C-734B-4BCC-AE01-12AEC06A1321Q28388002-8D481C2D-B894-4787-AECA-CB33C274FF0AQ30399727-2E5CD3E0-C907-43B6-AB89-74057050DB9CQ30830945-10EF23C3-CDE8-4DF3-BBFB-E2756B3C1E2FQ30874431-C9E55861-1739-4AFF-BF4A-45145E7D81D6Q33812170-DD0C9123-18ED-4F16-8EA6-62F554592A6DQ33826771-4F28C6E4-0243-4BBE-A815-07923FAA67C4Q33854726-7C99B7A8-A542-469E-9C5F-6EE768E3C956Q34040130-AD800855-0CDC-4D1B-BE27-523478DD21E3Q35549354-161405ED-7033-492F-AE09-A898E674B476Q36328631-CB8ED3B2-2799-4DAF-90BF-4DB29BBAC388Q37075676-12EC5C72-961A-42A4-BF18-BBE640A9670AQ38268195-F0EE43DC-B24C-4272-8EB6-5F5ED6571800Q43103830-7B5FCBD4-5A82-432C-A439-FF48F334C0A4Q43569431-928DA73A-F7FA-44BC-A028-347525C839D6Q44711945-E5F58F2A-EE83-413C-8CBF-DD3BD4CC87BBQ45090482-A71E7376-49E9-4464-91FB-D8E7ECC667D3Q52599153-62EBE313-023F-4DC7-8A1E-2EA9C00C6FD7Q52681001-A5766D59-C1C1-42BE-958E-48B9E036666FQ57583256-840CF82C-AC1D-4C44-A73D-E0B2AA92B219
P2860
Maintaining confidentiality of interim data to enhance trial integrity and credibility.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Maintaining confidentiality of interim data to enhance trial integrity and credibility.
@ast
Maintaining confidentiality of interim data to enhance trial integrity and credibility.
@en
type
label
Maintaining confidentiality of interim data to enhance trial integrity and credibility.
@ast
Maintaining confidentiality of interim data to enhance trial integrity and credibility.
@en
prefLabel
Maintaining confidentiality of interim data to enhance trial integrity and credibility.
@ast
Maintaining confidentiality of interim data to enhance trial integrity and credibility.
@en
P2093
P2860
P356
P1433
P1476
Maintaining confidentiality of interim data to enhance trial integrity and credibility.
@en
P2093
Andrew Moore
Katrina Sharples
Ralph Stewart
Thomas R Fleming
P2860
P304
P356
10.1177/1740774508089459
P577
2008-01-01T00:00:00Z